STOCK TITAN
  1. Home
  2. Sec-filings
  3. TARS
  4. [Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity

Tarsus (NASDAQ: TARS) grants director new stock options and RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PYOTT DAVID E I reported acquisition or exercise transactions in this Form 4 filing.

Tarsus Pharmaceuticals director David E. I. Pyott received new equity awards. On February 18, 2026, he was granted 5,893 stock options with a right to buy Tarsus common stock and 3,729 restricted stock units (RSUs).

The option grant will vest in three equal annual installments on February 18 of 2027, 2028, and 2029, contingent on his continuous service. Each RSU represents one share of common stock and will vest in three equal annual installments on March 15 of 2027, 2028, and 2029, also subject to continued service.

Positive

  • None.

Negative

  • None.
Insider PYOTT DAVID E I
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 5,893 $0.00 --
Grant/Award Restricted Stock Units 3,729 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 5,893 shares (Direct); Restricted Stock Units — 3,729 shares (Direct)
Footnotes (1)
  1. The option shares will vest in three equal annual installments on February 18th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PYOTT DAVID E I
(Last) (First) (Middle)
C/O TARSUS PHARMACEUTICALS
15440 LAGUNA CANYON ROAD, SUITE 160
(Street)
IRVINE CA 92618
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $63.27 02/18/2026 A 5,893 (1) 02/17/2036 Common Stock 5,893 $0 5,893 D
Restricted Stock Units (2) 02/18/2026 A 3,729 (3) (3) Common Stock 3,729 $0 3,729 D
Explanation of Responses:
1. The option shares will vest in three equal annual installments on February 18th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.
2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.
Remarks:
/s/ Scott Sieckert, Attorney-in-Fact 02/20/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Tarsus (TARS) director David Pyott receive in this Form 4?

Director David E. I. Pyott received a grant of 5,893 stock options and 3,729 restricted stock units from Tarsus Pharmaceuticals. These awards are part of his director compensation and are subject to multi-year vesting based on his continued service with the company.

How do David Pyott’s new Tarsus (TARS) stock options vest?

The 5,893 stock options granted to David Pyott vest in three equal annual installments. Vesting occurs on February 18 of 2027, 2028, and 2029, and is conditioned on his continuous service with Tarsus Pharmaceuticals throughout the vesting period.

What are the terms of the restricted stock units granted to David Pyott by Tarsus (TARS)?

David Pyott received 3,729 restricted stock units, each representing a contingent right to one Tarsus common share. These RSUs vest in three equal annual installments on March 15 of 2027, 2028, and 2029, provided he remains in continuous service to the company.

Does David Pyott pay anything per share for his new Tarsus (TARS) equity awards?

The Form 4 lists a transaction price of $0.0000 per unit for both the 5,893 stock options and 3,729 RSUs, indicating they were granted as compensation. Economic value will depend on Tarsus’s stock price when options are exercised or RSUs deliver shares.

Are David Pyott’s new Tarsus (TARS) equity awards classified as direct or indirect ownership?

Both the 5,893 stock options and 3,729 restricted stock units are reported as directly owned by David Pyott. The filing shows ownership type as direct, with no footnotes indicating holdings through a trust, LLC, or other indirect entity structure.